STING1 and neoplasm: Although recent advances in the development of cGAS-STING activators have contributed to tumor immunotherapy [17], the limitations of cGAS-STING activators, including drug resistance, low stability, poor half-life, off-target effects, and toxicity, have hampered their clinical application and greatly reduced their therapeutic efficacy.